Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stada and Xbrane Add Two To Biosimilar Development Alliance

Executive Summary

Stada and Xbrane have expanded their biosimilar development alliance by adding the Swedish firm’s certolizumab and nivolumab pre-clinical programs to the partnership.

You may also be interested in...



Stada Will Continue To Invest To Drive Growth

After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.

Nidda Will Squeeze Out Remaining Stada Shares

Stada’s owner has revealed plans to squeeze out the German firm’s remaining minority shareholders.

Sweden’s Xbrane Lays Out Ranibizumab Ambitions

Through a partnership with Stada, Sweden’s Xbrane is looking to introduce a biosimilar to Lucentis in major developed markets, including the EU and the US, where the hunt for a commercialization partner continues.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB140371

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel